Ultralow Background Near‐Infrared Fluorophores with Dual‐Channel Intraoperative Imaging Capability
Source abstract
Abstract
Abstract Two of the most pressing challenges facing bioimaging are nonspecific uptake of intravenously administered contrast agents and incomplete elimination of unbound targeted agents from the body. Designing a targeted contrast agent that shows fast clearance from background tissues and eventually the body after complete targeting is key to the success of image‐guided interventions. Here, this work describes the development of renally clearable near‐infrared contrast agents and their potential use for dual‐channel image‐guided tumor targeting. cRGD‐ZW800‐PEG (800 nm channel) and ZW700‐PEG (700 nm channel) are able to visualize tumor margins and tumor vasculature simultaneously and respectively. These targeted agents show rapid elimination from the bloodstream, followed by renal clearance, which together significantly lower off‐target background signals and potential toxicity. To demonstrate its applicability, this multispectral imaging is performed in various tumor‐bearing animal models including lung cancer, pancreatic neuroendocrine tumors, breast, and ovarian cancer.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Photoacoustic and Ultrasonic Imaging · Optical Imaging and Spectroscopy Techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Gordon Center for Medical Imaging Department of Radiology Massachusetts General Hospital and Harvard Medical School Boston MA 02114 USA
Department of Biomedical Sciences and Department of Thoracic and Cardiovascular Surgery, Korea University Guro Hospital College of Medicine Korea University Seoul 08308 South Korea
Funding
National Institutes of Health · National Institute of Biomedical Imaging and Bioengineering
References (34)
Show source-provided references
1. 10.1038/s41551-020-0536-710.1038/s41551-020-0536-7 ↗
2. 10.2310/7290.2010.0003410.2310/7290.2010.00034 ↗
3. 10.1038/nmat447610.1038/nmat4476 ↗
4. 10.1002/jso.2510510.1002/jso.25105 ↗
5. 10.1002/chem.20210281610.1002/chem.202102816 ↗
6. 10.1002/smll.20220272810.1002/smll.202202728 ↗
7. 10.1117/12.260841910.1117/12.2608419 ↗
8. 10.1038/s41467-022-31136-310.1038/s41467-022-31136-3 ↗
9. 10.1021/acs.jmedchem.8b0111510.1021/acs.jmedchem.8b01115 ↗
10. 10.1016/j.jtcvs.2015.05.01410.1016/j.jtcvs.2015.05.014 ↗
11. 10.1089/cren.2016.010410.1089/cren.2016.0104 ↗
12. 10.1021/acs.bioconjchem.9b0084410.1021/acs.bioconjchem.9b00844 ↗
13. 10.1158/0008-5472.CAN-04-195610.1158/0008-5472.CAN-04-1956 ↗
14. 10.1038/nnano.2009.31410.1038/nnano.2009.314 ↗
15. 10.1038/nbt.246810.1038/nbt.2468 ↗
16. 10.1002/anie.20210264010.1002/anie.202102640 ↗
17. 10.1002/anie.20110245910.1002/anie.201102459 ↗
18. 10.1007/s11307-015-0870-410.1007/s11307-015-0870-4 ↗
19. 10.1002/anie.20211733010.1002/anie.202117330 ↗
20. 10.1097/00006676-200208000-0002110.1097/00006676-200208000-00021 ↗
21. 10.1016/j.ijrobp.2017.06.210710.1016/j.ijrobp.2017.06.2107 ↗
22. 10.1038/s41592-022-01394-610.1038/s41592-022-01394-6 ↗
23. Urso R. · Riv. Eur. Sci. Med. Farmacol. · 2002 · 6 · 33
24. 10.1007/s11095-010-0363-810.1007/s11095-010-0363-8 ↗
25. 10.1111/j.1365-2885.2004.00605.x10.1111/j.1365-2885.2004.00605.x ↗
26. Lee J. H. · Quantum Imaging Med. Surg. · 2012 · 2 · 266
27. 10.1016/j.ajps.2020.07.00510.1016/j.ajps.2020.07.005 ↗
28. 10.1016/j.isci.2020.10100610.1016/j.isci.2020.101006 ↗
29. 10.1002/adhm.20190122310.1002/adhm.201901223 ↗
30. 10.7150/thno.869610.7150/thno.8696 ↗
31. 10.1016/j.cej.2018.01.00810.1016/j.cej.2018.01.008 ↗
32. 10.2310/7290.2011.0004810.2310/7290.2011.00048 ↗
33. 10.1038/sj.bjc.660157610.1038/sj.bjc.6601576 ↗
34. 10.3390/cancers1107097810.3390/cancers11070978 ↗